{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T11:38:54Z","timestamp":1785497934998,"version":"3.56.0"},"reference-count":169,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semcancer.2022.05.015","type":"journal-article","created":{"date-parts":[[2022,6,4]],"date-time":"2022-06-04T18:45:58Z","timestamp":1654368358000},"page":"834-850","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"P2","title":["Neoadjuvant immunotherapy in gastrointestinal cancers \u2013 The new standard of care?"],"prefix":"10.1016","volume":"86","author":[{"given":"Branka","family":"Petricevic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julijan","family":"Kabiljo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zirnbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Walczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Laengle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2022.05.015_bib1","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2022.05.015_bib2","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","article-title":"Multicenter International Study of Oxaliplatin\/5-Fluorouracil\/leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) investigators, oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer","volume":"350","author":"Andr\u00e9","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib3","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","article-title":"Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial","volume":"27","author":"Andr\u00e9","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib5","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann. Surg."},{"key":"10.1016\/j.semcancer.2022.05.015_bib7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/carcin\/bgi044","article-title":"Evolution of intratumoral genetic heterogeneity during colorectal cancer progression","volume":"26","author":"Losi","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.semcancer.2022.05.015_bib8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41419-020-2236-3","article-title":"Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer","volume":"11","author":"Ma","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.semcancer.2022.05.015_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41420-020-0284-1","article-title":"From threat to cure: understanding of virus-induced cell death leads to highly immunogenic oncolytic influenza viruses","volume":"6","author":"Kabiljo","year":"2020","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.semcancer.2022.05.015_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/cancers12010079","article-title":"Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy","author":"Kabiljo","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.semcancer.2022.05.015_bib11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib12","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.18416","article-title":"Clinical response to immunotherapy targeting programmed cell death receptor 1\/programmed cell death ligand 1 in patients with treatment-resistant microsatellite stable colorectal cancer with and without liver metastases","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw. Open."},{"key":"10.1016\/j.semcancer.2022.05.015_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002256","article-title":"Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy","volume":"9","author":"Lauret Marie Joseph","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib14","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1078-0432.CCR-19-2209","article-title":"Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen\u2013specific T cells","volume":"26","author":"Friedman","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.05.015_bib15","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1111\/cas.14158","article-title":"Supplementary granulocyte macrophage colony\u2010stimulating factor to chemotherapy and programmed death\u2010ligand 1 blockade decreases local recurrence after surgery in bladder cancer","volume":"110","author":"Miyake","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2022.05.015_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001906","article-title":"Tracking genomic cancer evolution for precision medicine: the lung TRACERx study","volume":"12","author":"Jamal-Hanjani","year":"2014","journal-title":"PLoS Biol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib17","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1158\/1078-0432.CCR-14-2413","article-title":"Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity","volume":"21","author":"Kim","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.05.015_bib18","article-title":"Genomic evolution and diverse models of systemic metastases in colorectal cancer","author":"Chen","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.semcancer.2022.05.015_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2019.07.018","article-title":"Defining the \u201cMetastasome\u201d: perspectives from the genome and molecular landscape in colorectal cancer for metastasis evolution and clinical consequences","volume":"60","author":"Allgayer","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib20","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1073\/pnas.1121629109","article-title":"Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma","volume":"109","author":"Edris","year":"2012","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.semcancer.2022.05.015_bib21","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/s41467-020-15129-8","article-title":"Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity","volume":"11","author":"von Roemeling","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.05.015_bib22","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Disco"},{"key":"10.1016\/j.semcancer.2022.05.015_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.immuni.2017.03.013","article-title":"Fc-optimized anti-CD25 depletes tumor-infiltrating regulatory T cells and synergizes with PD-1 blockade to eradicate established tumors","volume":"46","author":"Arce Vargas","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2022.05.015_bib24","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1158\/1078-0432.CCR-18-0762","article-title":"Anti-CTLA-4 immunotherapy does not deplete Foxp3 \u00fe regulatory T cells (Tregs) in human cancers","volume":"25","author":"Sharma","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.05.015_bib26","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib27","doi-asserted-by":"crossref","first-page":"eaat7807","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.semcancer.2022.05.015_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2022.05.015_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib31","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1581530","article-title":"Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2022.05.015_bib32","doi-asserted-by":"crossref","first-page":"226ra32","DOI":"10.1126\/scitranslmed.3008095","article-title":"Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy","volume":"6","author":"Zamarin","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib33","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1546068","article-title":"Batf3 + DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy","volume":"8","author":"Liu","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2022.05.015_bib34","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124507","article-title":"Tumor-draining lymph nodes are pivotal in PD-1\/PD-L1 checkpoint therapy","volume":"3","author":"Fransen","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.semcancer.2022.05.015_bib35","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.cell.2019.10.003","article-title":"Landscape and dynamics of single immune cells in hepatocellular carcinoma","volume":"179","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2022.05.015_bib36","doi-asserted-by":"crossref","first-page":"eabg8693","DOI":"10.1126\/scitranslmed.abg8693","article-title":"Dual targeting of CTLA-4 and CD47 on T reg cells promotes immunity against solid tumors","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib37","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 Immune Checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2022.05.015_bib38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004306","article-title":"Harnessing radiotherapy-induced NK-cell activity by combining DNA damage\u2013response inhibition and immune checkpoint blockade","volume":"10","author":"Patin","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib39","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2025930118","article-title":"Antitumor efficacy and reduced toxicity using an anti-CD137 Probody therapeutic","volume":"118","author":"Etxeberria","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.semcancer.2022.05.015_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1158\/0008-5472.CAN-17-2415","article-title":"Perioperative, spatiotemporally coordinated activation of T and NK cells prevents recurrence of pancreatic cancer","volume":"78","author":"Brooks","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib41","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41590-019-0561-4","article-title":"Immunological impact of cell death signaling driven by radiation on the tumor microenvironment","volume":"21","author":"Rodriguez-Ruiz","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ccell.2020.11.009","article-title":"Immunomodulation by targeted anticancer agents","volume":"39","author":"Petroni","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2022.05.015_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000195","article-title":"Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis","volume":"8","author":"Laengle","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-019-0272-7","article-title":"Oncolysis without viruses \u2014 inducing systemic anticancer immune responses with local therapies","volume":"17","author":"Kepp","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological effects of conventional chemotherapy and targeted anticancer agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2022.05.015_bib46","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1084\/jem.20050915","article-title":"Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death","volume":"202","author":"Casares","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib47","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4\u2013dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib48","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/cdd.2013.60","article-title":"Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines","volume":"21","author":"Hannani","year":"2014","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.semcancer.2022.05.015_bib49","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.semcancer.2022.05.015_bib50","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1126\/science.1240537","article-title":"The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide","volume":"342","author":"Viaud","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2022.05.015_bib51","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.canlet.2019.08.005","article-title":"Cisplatin increases PD-L1 expression and optimizes immune check-point blockade in non-small cell lung cancer","volume":"464","author":"Fournel","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.semcancer.2022.05.015_bib52","doi-asserted-by":"crossref","first-page":"6406","DOI":"10.1158\/1078-0432.CCR-19-1259","article-title":"Anti-OX40 antibody directly enhances the function of tumor-reactive CD8 + T cells and synergizes with PI3K\u03b2 inhibition in PTEN loss melanoma","volume":"25","author":"Peng","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.05.015_bib53","first-page":"1141","article-title":"Cisplatin alters antitumor immunity and synergizes with PD-1\/PD-L1 inhibition in head and neck squamous cell carcinoma, cancer","volume":"5","author":"Tran","year":"2017","journal-title":"Immunol. Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib54","article-title":"Immune checkpoints and liver resection after neoadjuvant chemotherapy including bevacizumab in patients with microsatellite-stable colorectal liver metastases","author":"Stift","year":"2021","journal-title":"HPB"},{"key":"10.1016\/j.semcancer.2022.05.015_bib55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2022.05.015_bib56","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.lungcan.2020.05.023","article-title":"Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells","volume":"146","author":"Otsuka","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib57","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti\u2013PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib58","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/ijms22020535","article-title":"Combination of cisplatin and irradiation induces immunogenic cell death and potentiates postirradiation Anti\u2013PD-1 treatment efficacy in urothelial carcinoma","volume":"22","author":"Fukushima","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2022.05.015_bib59","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/2326-6066.CIR-18-0654","article-title":"Radiotherapy and cisplatin increase immunotherapy efficacy by enabling local and systemic intratumoral T-cell activity","volume":"7","author":"Kroon","year":"2019","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.102016","article-title":"Sensitization of ovarian tumor to immune checkpoint blockade by boosting senescence-associated secretory phenotype","volume":"24","author":"Hao","year":"2021","journal-title":"IScience"},{"key":"10.1016\/j.semcancer.2022.05.015_bib61","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2022.05.015_bib62","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.4049\/jimmunol.181.5.3099","article-title":"Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells","volume":"181","author":"Matsumura","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib63","doi-asserted-by":"crossref","first-page":"11934","DOI":"10.1038\/s41598-018-30417-6","article-title":"Inhibiting the CD8+ T cell infiltration in the tumor microenvironment after radiotherapy is an important mechanism of radioresistance","volume":"8","author":"Chen","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcancer.2022.05.015_bib64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1078\/0171-2985-00078","article-title":"Workshop R: tumor immunology, abstract R1 bis R30","volume":"204","author":"Ganss","year":"2001","journal-title":"Immunobiology"},{"key":"10.1016\/j.semcancer.2022.05.015_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s12032-018-1080-0","article-title":"The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma","volume":"35","author":"Uryvaev","year":"2018","journal-title":"Med. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib66","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157164","article-title":"Optimizing timing of immunotherapy improves control of tumors by hypofractionated radiation therapy","volume":"11","author":"Young","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semcancer.2022.05.015_bib67","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2022.05.015_bib68","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.ijrobp.2016.07.005","article-title":"A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma","volume":"96","author":"Hiniker","year":"2016","journal-title":"Int. J. Radiat. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib69","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1158\/0008-5472.CAN-14-1258","article-title":"Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade","volume":"74","author":"Dovedi","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib70","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib71","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3171\/2016.9.JNS161585","article-title":"The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab","volume":"127","author":"Cohen-Inbar","year":"2017","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.semcancer.2022.05.015_bib72","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1007\/s00066-018-1356-5","article-title":"Long-term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters","volume":"194","author":"Schmidberger","year":"2018","journal-title":"Strahlenther. Und Onkol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib73","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1002\/cncr.30138","article-title":"Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery","volume":"122","author":"Qian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib74","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1093\/neuonc\/noz046","article-title":"The impact of sequencing PD-1\/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis","volume":"21","author":"Kotecha","year":"2019","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib75","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1158\/1078-0432.CCR-17-3573","article-title":"IDO1 inhibition synergizes with radiation and PD-1 blockade to durably increase survival against advanced glioblastoma","volume":"24","author":"Ladomersky","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.05.015_bib76","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","article-title":"Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.05.015_bib77","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?","volume":"9","author":"Demaria","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib78","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1395996","article-title":"PD-1 blockade reverses adaptive immune resistance induced by high-dose hypofractionated but not low-dose daily fractionated radiation","volume":"7","author":"Morisada","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2022.05.015_bib79","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.semcancer.2022.05.015_bib80","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-17-0581","article-title":"Exosomes shuttle TREX1-Sensitive IFN-Stimulatory dsDNA from Irradiated Cancer Cells to DCs","volume":"6","author":"Diamond","year":"2018","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib81","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-019-0588-y","article-title":"Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity","volume":"7","author":"Minniti","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib82","doi-asserted-by":"crossref","first-page":"5058","DOI":"10.1158\/1078-0432.CCR-17-3427","article-title":"Elective nodal irradiation attenuates the combinatorial efficacy of stereotactic radiation therapy and immunotherapy","volume":"24","author":"Marciscano","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2022.05.015_bib83","doi-asserted-by":"crossref","first-page":"eaam7577","DOI":"10.1126\/scitranslmed.aam7577","article-title":"Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade","volume":"10","author":"Samson","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib84","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2174\/1568009617666170222125035","article-title":"Clinical trials with oncolytic measles virus: current status and future prospects","volume":"18","author":"Msaouel","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.semcancer.2022.05.015_bib85","first-page":"8188","article-title":"A genetically engineered influenza A virus with ras-dependent oncolytic properties","volume":"61","author":"Bergmann","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib86","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib87","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib88","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib89","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcancer.2022.05.015_bib90","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.surg.2016.08.045","article-title":"Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo","volume":"161","author":"Hock","year":"2017","journal-title":"Surgery"},{"key":"10.1016\/j.semcancer.2022.05.015_bib91","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1038\/mt.2011.29","article-title":"Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF","volume":"19","author":"Zhang","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.semcancer.2022.05.015_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2022.05.015_bib93","doi-asserted-by":"crossref","first-page":"14987","DOI":"10.1073\/pnas.0806075105","article-title":"CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients","volume":"105","author":"Liakou","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.semcancer.2022.05.015_bib94","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib95","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 tria","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2022.05.015_bib96","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.annonc.2021.06.014","article-title":"VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC","volume":"32","author":"Schmid","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib97","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib98","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8503","article-title":"Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3)","volume":"37","author":"Kwiatkowski","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib99","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1093\/annonc\/mdz064.014","article-title":"IMpower030: Phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy","volume":"30","author":"Peters","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib100","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2021-CT003","article-title":"Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial","volume":"81","author":"Forde","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib101","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.8503","article-title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC)","volume":"39","author":"Spicer","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib102","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib103","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41591-020-01211-7","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib104","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.4506","article-title":"A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS)","volume":"36","author":"Powles","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib106","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5020","article-title":"Biomarker analysis and updated clinical follow-up of preoperative ipilimumab (ipi) plus nivolumab (nivo) in stage III urothelial cancer (NABUCCO)","volume":"38","author":"Van Dijk","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib107","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS586","article-title":"INTACT: phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer\u2014SWOG\/NRG1806","volume":"38","author":"Singh","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS5093","article-title":"Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992.","volume":"38","author":"Balar","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib109","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4517","article-title":"Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): a multicenter, single-arm, phase 2 trial","volume":"39","author":"Funt","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.6008","article-title":"Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC)","volume":"39","author":"Uppaluri","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib111","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib112","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib113","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib114","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors with Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trecan.2016.02.004","article-title":"The immune biology of microsatellite-unstable cancer","volume":"2","author":"Kloor","year":"2016","journal-title":"Trends Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib116","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2022.05.015_bib117","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib118","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1711650","article-title":"PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient\/microsatellite instability-high colorectal cancer","volume":"9","author":"Liu","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.semcancer.2022.05.015_bib119","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.1158\/1078-0432.CCR-21-0163","article-title":"Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases","volume":"27","author":"Kanikarla Marie","year":"2021","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.semcancer.2022.05.015_bib120","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib121","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","article-title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Argil\u00e9s","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib122","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.7150\/thno.24699","article-title":"DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells","volume":"8","author":"Laengle","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.semcancer.2022.05.015_bib123","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.semcancer.2022.05.015_bib124","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.semcancer.2022.05.015_bib125","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib126","doi-asserted-by":"crossref","first-page":"v50","DOI":"10.1093\/annonc\/mdw329","article-title":"Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Lordick","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib127","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib128","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000667","article-title":"Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer","volume":"8","author":"Stary","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib129","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001610","article-title":"Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer","volume":"9","author":"Seo","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib130","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.4100","article-title":"Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer","volume":"38","author":"Yuki","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib131","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.100","article-title":"VOLTAGE-B study: nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy","volume":"38","author":"Kato","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib132","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib133","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib134","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.201","article-title":"Perioperative FLOT plus anti-PD-L1 avelumab (FLOT-A) in resectable oesophagogastric adenocarcinoma (OGA): Interim safety analysis results from the ICONIC trial","volume":"39","author":"Athauda","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4045","article-title":"A phase II feasibility trial of neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: The PERFECT trial","volume":"37","author":"van den Ende","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib136","article-title":"Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: early efficacy results from Big Ten Cancer Research Consortium study","volume":"37","author":"Mamdani","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib137","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4064","article-title":"A phase II\/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in\u2014A trial of the ECOG-ACRIN Cancer Research Group (EA2174)","volume":"39","author":"Eads","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib138","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4041","article-title":"Safety of neoadjuvant chemoradiation (CRT) in combination with avelumab (A) in the treatment of resectable esophageal and gastroesophageal junction (E\/GEJ) cancer","volume":"37","author":"Uboha","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib139","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.4_suppl.142","article-title":"Neoadjuvant nivolumab plus concurrent chemoradiation in stage II\/III esophageal\/gastroesophageal junction cancer","volume":"37","author":"Kelly","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib140","article-title":"A prospective, phase II, single-arm study of neoadjuvant\/conversion therapy with camrelizumab, apatinib, S-1 \u00b1 oxaliplatin for locally advanced cT4a\/bN+ gastric cancer","volume":"39","author":"Li","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib141","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4136","article-title":"KEYNOTE-585: phase 3 study of chemotherapy (chemo) + pembrolizumab (pembro) vs chemo + placebo as neoadjuvant\/adjuvant treatment for patients (pts) with gastric or gastroesophageal junction (G\/GEJ) cancer","volume":"36","author":"Bang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib142","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS197","article-title":"A phase II study of chemotherapy and immune checkpoint blockade with pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma","volume":"36","author":"Oberstein","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib143","article-title":"Safety of perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: an interim safety analysis of the DANTE, a randomized, open-label phase II trial of the German Gastric Group at the","volume":"38","author":"Al-Batran","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib144","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4128","article-title":"Randomized multicenter phase Ib\/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer","volume":"39","author":"Rahma","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib145","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.4_suppl.380","article-title":"Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer","volume":"36","author":"Wang-Gillam","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib146","article-title":"Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC","volume":"38","author":"Kaseb","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib147","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e16542","article-title":"Preliminary results of a phase II study of neoadjuvant immune checkpoint inhibitor IMC-001 (anti-PD-L1 monoclonal antibody) in patients with resectable gastrointestinal cancers (NeoChance Study)","volume":"38","author":"Im","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib148","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e15169","article-title":"Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502)","volume":"37","author":"Sinicrope","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib149","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3615","article-title":"POLEM: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III dMMR or POLE exonuclease domain mutant colon cancer\u2014a phase III randomized study","volume":"37","author":"Lau","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3623","article-title":"Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial","volume":"39","author":"Laengle","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib151","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS272","article-title":"A phase II study to evaluate safety and efficacy of neoadjuvant pembrolizumab and radiotherapy in localized MSS rectal cancer","volume":"38","author":"Kossler","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib152","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS264","article-title":"NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer","volume":"38","author":"George","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib153","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS3622","article-title":"Phase II trial PD-L1\/PD-1 blockade avelumab with chemoradiotherapy for locally advanced resectable T3B-4\/N1-2 rectal cancer: the ave-Rec trial","volume":"37","author":"Michael","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib154","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.TPS259","article-title":"A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer (PANDORA)","volume":"38","author":"Tamberi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib155","article-title":"Pd1 antibody sintilimab for dMMR\/MSI-H locally advanced rectal cancer: an open-label, phase 2, single-arm study (cohort A)","volume":"39","author":"Chen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib156","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.3511","article-title":"Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study","volume":"39","author":"Salvatore","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib157","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.3_suppl.8","article-title":"NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)\u2014Pembrolizumab experimental arm (EA) primary results","volume":"39","author":"Rahma","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib158","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.4_suppl.139","article-title":"Short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma","volume":"38","author":"Shamseddine","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib159","article-title":"Short-course radiotherapy and subsequent CAPOX plus camrelizumab followed by delayed surgery for locally advanced rectal cancer:Short-term results of a phase II trial","volume":"39","author":"Lin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib160","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.semcancer.2022.05.015_bib161","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib162","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib163","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.semcancer.2022.05.015_bib164","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib165","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib166","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non\u2013small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.semcancer.2022.05.015_bib167","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","article-title":"Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma","volume":"4","author":"Shoushtari","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib168","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2022.05.015_bib169","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J. Immunother. Cancer"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X22001262?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X22001262?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:22:00Z","timestamp":1760919720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X22001262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":169,"alternative-id":["S1044579X22001262"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2022.05.015","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant immunotherapy in gastrointestinal cancers \u2013 The new standard of care?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2022.05.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}